Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28299360 | 0.93 | ALOX15 (0.52) | ALOX15HIF1AEPAS1TSHRCYP3A4 | |
| SCHEMBL8374951 | 0.92 | ALOX15 (0.55) | ALOX15HIF1AEPAS1TSHRKMT2A | |
| SCHEMBL10524674 | 0.89 | ALOX15 (0.52) | ALOX15HIF1AEPAS1TSHR | |
| SCHEMBL8375220 | 0.87 | ALOX15 (0.50) | ALOX15HIF1AEPAS1TSHR | |
| SCHEMBL28480784 | 0.86 | ALOX15 (0.57) | ALOX15HIF1AEPAS1TSHRKMT2A | |
| SCHEMBL454435 | 0.86 | ALOX15 (0.57) | ALOX15HIF1AEPAS1TSHRKMT2A | |
| SCHEMBL8160898 | 0.86 | ALOX15 (0.57) | ALOX15HIF1AEPAS1TSHRKMT2A | |
| SCHEMBL3165667 | 0.84 | ALOX15 (0.47) | ALOX15HIF1AEPAS1TSHR | |
| SCHEMBL11651862 | 0.84 | ALOX15 (0.42) | ALOX15HIF1AEPAS1 | |
| SCHEMBL27995055 | 0.84 | ALOX15 (0.55) | ALOX15HIF1AEPAS1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338225-B2 | 2,2,6-trimethyl-4,5-dihydro-3H-oxepine as aroma ingredient | BASF SE (DE) | 2025-06-24 | — | — | US | claimed |
| WO-2024257921-A1 | ECO-FRIENDLY CUP HOLDER AND MANUFACTURING METHOD THEREFOR | 주식회사 에스엠텍스타일 | 2024-12-19 | — | — | WO | claimed |
| US-20240417153-A1 | ECO-FRIENDLY CUP HOLDER AND METHOD OF MANUFACTURING SAME | SM TEXTILE CO., LTD. (KR) | 2024-12-19 | — | — | US | claimed |
| EP-4021900-B1 | 2,2,6-TRIMETHYL-4,5-DIHYDRO-3H-OXEPINE AS AROMA INGREDIENT | BASF SE (DE) | 2023-10-11 | — | — | EP | claimed |
| US-20220281834-A1 | 2,2,6-TRIMETHYL-4,5-DIHYDRO-3H-OXEPINE AS AROMA INGREDIENT | BASF SE (DE) | 2022-09-08 | — | — | US | claimed |
| US-20250380732-A1 | AEROSOLISABLE FORMULATION | NICOVENTURES TRADING LTD (GB) | 2025-12-18 | — | — | US | disclosed |
| US-20250241356-A1 | ORAL COMPOSITION COMPRISING RECEPTOR MODULATOR | DANIEL MICHAEL S (US) | 2025-07-31 | — | — | US | disclosed |
| US-12338225-B2 | 2,2,6-trimethyl-4,5-dihydro-3H-oxepine as aroma ingredient | BASF SE (DE) | 2025-06-24 | — | — | US | disclosed |
| EP-4543230-A1 | AEROSOLISABLE FORMULATION | Nicoventures Trading Limited (GB) | 2025-04-30 | — | — | EP | disclosed |
| EP-4543229-A1 | ORAL COMPOSITION COMPRISING A RECEPTOR MODULATOR | Nicoventures Trading Limited (GB) | 2025-04-30 | — | — | EP | disclosed |
| US-12247181-B2 | Cyclopentanone compounds | FIRMENICH SA (CH) | 2025-03-11 | — | — | US | disclosed |
| US-20240417153-A1 | ECO-FRIENDLY CUP HOLDER AND METHOD OF MANUFACTURING SAME | SM TEXTILE CO., LTD. (KR) | 2024-12-19 | — | — | US | disclosed |
| US-5985618-A | ENZYMATICALLY HYDROLYZING | CIST-BROCADES, N.V. (NL) | 1999-11-16 | — | — | US | disclosed |
| EP-0416713-B2 | Process for obtaining aroma components and aromas from their precursors of a glycosidic nature, and aroma components and aromas thereby obtained | DSM NV (NL) | 1999-06-23 | — | — | EP | disclosed |
| EP-0900375-A1 | PHARMACEUTICAL GRADE BOTANICAL DRUGS | Pharmaprint, Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997039355-A1 | PHARMACEUTICAL GRADE BOTANICAL DRUGS | PHARMAPRINT, INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5573926-A | HYDROLYSIS | GIST-BROCADES, N.V. (NL) | 1996-11-12 | — | — | US | disclosed |
| WO-1991003174-A1 | PROCESS FOR OBTAINING AROMA COMPONENTS AND AROMAS FROM THEIR PRECURSORS OF A GLYCOSIDIC NATURE, AND AROMA COMPONENTS AND AROMAS THEREBY OBTAINED | GIST-BROCADES N.V. (NL) | 1991-03-21 | — | — | WO | disclosed |
| EP-0416713-A1 | Process for obtaining aroma components and aromas from their precursors of a glycosidic nature, and aroma components and aromas thereby obtained | GIST-BROCADES N.V. (NL) | 1991-03-13 | — | — | EP | disclosed |
| US-3931250-A | 1-TETRAHYDROFURYL, 1-FURYL ETHANE | FIRMENICH SA (CH) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247181-B2 | Cyclopentanone compounds | PTGIS, CYP1B1, HPGD | ALOX15 127/4885HIF1A 623/4885EPAS1 469/4885 |
| US-12338225-B2 | 2,2,6-trimethyl-4,5-dihydro-3H-oxepine as aroma ingredient | DRD4, HTR5A, HTR4 | ALOX15 350/4885HIF1A 275/4885EPAS1 1914/4885 |
| US-20220281834-A1 | 2,2,6-TRIMETHYL-4,5-DIHYDRO-3H-OXEPINE AS AROMA INGREDIENT | DRD4, HTR5A, HTR4 | ALOX15 350/4885HIF1A 275/4885EPAS1 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.